...
机译:新诊断为急性白血病的患者的浸润性真菌病† sup> ‡ sup>
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts|Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts|Harvard Medical School, Boston, Massachusetts;
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts|Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts|Harvard Medical School, Boston, Massachusetts;
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts|Harvard School of Public Health, Boston, Massachusetts;
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts|Harvard Medical School, Boston, Massachusetts;
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts|Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts|Harvard Medical School, Boston, Massachusetts;
机译:新诊断为急性白血病的患者的侵袭性真菌病。
机译:侵袭性真菌疾病的化学治疗前危险因素:对1192例新诊断的急性髓性白血病患者的前瞻性分析(SEIFEM 2010-一项多中心研究)| Business Wire血液学
机译:2009年至2011年三级癌症中心新诊断的急性髓细胞性白血病患者在一级抗真菌药物预防期间的侵袭性真菌感染发生率
机译:急性发作期慢性肺源性心脏病(CPHO)的诊断与治疗的实现
机译:根据2017年日本成人白血病研究组(JALSG)AML201研究治疗的成人急性髓性白血病患者的遗传学预测,根据2017 ELN风险分层进行预后分析
机译:浸润性真菌疾病的化学治疗前危险因素:对1192例新诊断的急性髓性白血病患者的前瞻性分析(SEIFEM 2010-一项多中心研究)
机译:浸润性真菌疾病的化学治疗前危险因素:对1192例新诊断的急性髓性白血病患者的前瞻性分析(SEIFEM 2010-一项多中心研究)